Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation

被引：5
作者：
Morgensztern, Daniel [1 ]
Govindan, Ramaswamy [1 ]
机构：
[1] Washington Univ, Div Med Oncol, Dept Med, Sch Med, St Louis, MO 63110 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 12期
关键词：
CELL LUNG-CANCER; CHECKPOINT INHIBITORS; SURVIVAL;
D O I：
10.1016/j.jtho.2021.07.034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1999 / 2001
页数：3
相关论文
共 17 条
  • [1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [2] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
    Aredo, Jacqueline V.
    Mambetsariev, Isa
    Hellyer, Jessica A.
    Amini, Arya
    Neal, Joel W.
    Padda, Sukhmani K.
    McCoach, Caroline E.
    Riess, Jonathan W.
    Cabebe, Elwyn C.
    Naidoo, Jarushka
    Abuali, Tariq
    Salgia, Ravi
    Loo Jr, Billy W.
    Diehn, Maximilian
    Han, Summer S.
    Wakelee, Heather A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 1030 - 1041
  • [3] Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
    Dovedi, Simon J.
    Adlard, Amy L.
    Lipowska-Bhalla, Grazyna
    McKenna, Conor
    Jones, Sherrie
    Cheadle, Eleanor J.
    Stratford, Ian J.
    Poon, Edmund
    Morrow, Michelle
    Stewart, Ross
    Jones, Hazel
    Wilkinson, Robert W.
    Honeychurch, Jamie
    Illidge, Tim M.
    [J]. CANCER RESEARCH, 2014, 74 (19) : 5458 - 5468
  • [4] Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Wood, Douglas E.
    Aisner, Dara L.
    Akerley, Wallace
    Bauman, Jessica R.
    Bharat, Ankit
    Bruno, Debora S.
    Chang, Joe Y.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Dilling, Thomas J.
    Dowell, Jonathan
    Gettinger, Scott
    Gubens, Matthew A.
    Hegde, Aparna
    Hennon, Mark
    Lackner, Rudy P.
    Lanuti, Michael
    Leal, Ticiana A.
    Lin, Jules
    Loo, Billy W., Jr.
    Lovly, Christine M.
    Martins, Renato G.
    Massarelli, Erminia
    Morgensztern, Daniel
    Ng, Thomas
    Otterson, Gregory A.
    Patel, Sandip P.
    Riely, Gregory J.
    Schild, Steven E.
    Shapiro, Theresa A.
    Singh, Aditi P.
    Stevenson, James
    Tam, Alda
    Yanagawa, Jane
    Yang, Stephen C.
    Gregory, Kristina M.
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (03): : 254 - 266
  • [5] Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
    Faivre-Finn, Corinne
    Vicente, David
    Kurata, Takayasu
    Planchard, David
    Paz-Ares, Luis
    Vansteenkiste, Johan F.
    Spigel, David R.
    Garassino, Marina C.
    Reck, Martin
    Senan, Suresh
    Naidoo, Jarushka
    Rimner, Andreas
    Wu, Yi-Long
    Gray, Jhanelle E.
    Ozguroglu, Mustafa
    Lee, Ki H.
    Cho, Byoung C.
    Kato, Terufumi
    de Wit, Maike
    Newton, Michael
    Wang, Lu
    Thiyagarajah, Piruntha
    Antonia, Scott J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 860 - 867
  • [6] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
    Gainor, Justin F.
    Shaw, Alice T.
    Sequist, Lecia V.
    Fu, Xiujun
    Azzoli, Christopher G.
    Piotrowska, Zofia
    Huynh, Tiffany G.
    Zhao, Ling
    Fulton, Linnea
    Schultz, Katherine R.
    Howe, Emily
    Farago, Anna F.
    Sullivan, Ryan J.
    Stone, James R.
    Digumarthy, Subba
    Moran, Teresa
    Hata, Aaron N.
    Yagi, Yukako
    Yeap, Beow Y.
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4585 - 4593
  • [7] Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
    Galluzzi, Lorenzo
    Humeau, Juliette
    Buque, Aitziber
    Zitvogel, Laurence
    Kroemer, Guido
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (12) : 725 - 741
  • [8] Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
    Garassino, Marina Chiara
    Cho, Byoung-Chul
    Kim, Joo-Hang
    Mazieres, Julien
    Vansteenkiste, Johan
    Lena, Herve
    Jaime, Jesus Corral
    Gray, Jhanelle E.
    Powderly, John
    Chouaid, Christos
    Bidoli, Paolo
    Wheatley-Price, Paul
    Park, Keunchil
    Soo, Ross A.
    Huang, Yifan
    Wadsworth, Catherine
    Dennis, Phillip A.
    Rizvi, Naiyer A.
    [J]. LANCET ONCOLOGY, 2018, 19 (04) : 521 - 536
  • [9] EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Hastings, K.
    Yu, H. A.
    Wei, W.
    Sanchez-Vega, F.
    DeVeaux, M.
    Choi, J.
    Rizvi, H.
    Lisberg, A.
    Truini, A.
    Lydon, C. A.
    Liu, Z.
    Henick, B. S.
    Wurtz, A.
    Cai, G.
    Plodkowski, A. J.
    Long, N. M.
    Halpenny, D. F.
    Killam, J.
    Oliva, I
    Schultz, N.
    Riely, G. J.
    Arcila, M. E.
    Ladanyi, M.
    Zelterman, D.
    Herbst, R. S.
    Goldberg, S. B.
    Awad, M. M.
    Garon, E. B.
    Gettinger, S.
    Hellmann, M. D.
    Politi, K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1311 - 1320
  • [10] Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
    Heinhuis, K. M.
    Ros, W.
    Kok, M.
    Steeghs, N.
    Beijnen, J. H.
    Schellens, J. H. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (02) : 219 - 235
12